May 2, 2023 | News, Press Releases
COMPASS Pathways and MAPS PBC submitted joint application for new code to facilitate access to psychedelic therapy in the US, if approved London, UK and San Jose, US – May 2, 2023 COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company...
Apr 5, 2023 | News, Press Releases
Interim results show improvements in PTSD symptom severity lasted at least six months after the last treatment session Findings are consistent with previously published Phase 2 data[1] on the sustained effect of MDMA-assisted therapy for the treatment of PTSD SAN...
Jan 19, 2023 | News, Press Releases
Results demonstrate a biological correlation between reduction in PTSD severity and treatment with MDMA-assisted therapy in veterans and first responders Study sheds light on neurological mechanisms that drive MDMA-assisted therapy in PTSD SAN JOSE, Calif.,...
Jan 5, 2023 | News, Press Releases
Results met study pre-specified primary and key secondary endpoints and will support new drug application submission expected in third quarter of 2023 No serious adverse events observed in the MDMA group If approved, MAPS PBC’s MDMA-assisted therapy could be the...
Nov 17, 2022 | Press Releases, News
Top-line data expected in the first quarter of 2023 Data to be part of new drug application submission expected in third quarter of 2023 SAN JOSE, Calif., November 17, 2022—MAPS Public Benefit Corporation (“MAPS PBC”), a private company dedicated to the development...
Oct 4, 2022 | News, Press Releases
The new chairman brings critical commercial expertise and pharmaceutical leadership needed during MAPS PBC’s growth phase MDMA-assisted therapy, a novel treatment for post-traumatic stress disorder (PTSD) with FDA breakthrough therapy designation, is on track for new...
